Urinary Soluble CD163: A Novel Biomarker Suggests Who Should Receive Glucocorticoids in IgA Nephropathy.
作者信息
Li Guisen, Thanabalasingam Susan J
机构信息
Renal Department and Nephrology Institute, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Sichuan Clinical Research Centre for Kidney Diseases, Chengdu, China.
Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
出版信息
Kidney Int Rep. 2024 Aug 9;9(10):2848-2850. doi: 10.1016/j.ekir.2024.08.011. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
Urinary Soluble CD163: A Novel Biomarker Suggests Who Should Receive Glucocorticoids in IgA Nephropathy.尿可溶性CD163：一种新型生物标志物提示IgA肾病患者谁应接受糖皮质激素治疗。
Kidney Int Rep. 2024 Aug 9;9(10):2848-2850. doi: 10.1016/j.ekir.2024.08.011. eCollection 2024 Oct.
2
Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status.尿可溶性 CD163 水平可预测 IgA 肾病缓解状态。
Front Immunol. 2021 Dec 23;12:769802. doi: 10.3389/fimmu.2021.769802. eCollection 2021.
3
Urinary Soluble CD163: a Novel Noninvasive Biomarker of Activity for Lupus Nephritis.尿可溶性 CD163：狼疮肾炎活动的新型无创生物标志物。
J Am Soc Nephrol. 2020 Jun;31(6):1335-1347. doi: 10.1681/ASN.2019121285. Epub 2020 Apr 16.
4
Correlation of Urinary Soluble CD163 Levels With Disease Activity and Treatment Response in IgA Nephropathy.IgA肾病患者尿可溶性CD163水平与疾病活动及治疗反应的相关性
Kidney Int Rep. 2024 Aug 3;9(10):3016-3026. doi: 10.1016/j.ekir.2024.07.031. eCollection 2024 Oct.
5
Increased excretion of tumor necrosis factor alpha and interleukin 1 beta in urine from patients with IgA nephropathy and Schönlein-Henoch purpura.IgA肾病和过敏性紫癜患者尿液中肿瘤坏死因子α和白细胞介素1β排泄增加。
Nephron. 1996;74(1):79-88. doi: 10.1159/000189285.
6
Tonsillectomy with methylprednisolone pulse therapy as rescue treatment for steroid-resistant IgA nephropathy in children.扁桃体切除术联合甲泼尼龙冲击疗法作为儿童激素抵抗型IgA肾病的挽救治疗
Tohoku J Exp Med. 2009 May;218(1):11-6. doi: 10.1620/tjem.218.11.
7
Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis.尿可溶性 CD163 与经活检证实的抗中性粒细胞胞质抗体相关性肾小球肾炎的疾病活动度。
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1740-1748. doi: 10.2215/CJN.07210520. Epub 2020 Nov 17.
8
Clinical-pathologic significance of CD163 positive macrophage in IgA nephropathy patients with crescents.CD163阳性巨噬细胞在伴有新月体的IgA肾病患者中的临床病理意义
Int J Clin Exp Med. 2015 Jun 15;8(6):9299-305. eCollection 2015.
9
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.肾素-血管紧张素系统双重阻断对两组IgA肾病和糖尿病肾病患者尿蛋白及转化生长因子-β排泄的影响。
Clin Nephrol. 2003 Nov;60(5):318-26. doi: 10.5414/cnp60318.
10
Deterioration of urinary findings after tonsil stimulation in patients with IgA nephropathy.IgA肾病患者扁桃体刺激后尿液检查结果的恶化。
Acta Otolaryngol Suppl. 1996;523:169-71.
本文引用的文献
1
Novel Treatment Paradigms: Primary IgA Nephropathy.新型治疗模式：原发性IgA肾病
Kidney Int Rep. 2023 Dec 1;9(2):203-213. doi: 10.1016/j.ekir.2023.11.026. eCollection 2024 Feb.
2
The Treatment of Primary IgA Nephropathy: Change, Change, Change.原发性 IgA 肾病的治疗：改变，改变，改变。
Am J Kidney Dis. 2024 Feb;83(2):229-240. doi: 10.1053/j.ajkd.2023.08.007. Epub 2023 Sep 23.
3
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.在原发性 IgA 肾病（NefIgArd）患者中，布地奈德靶向释放制剂的疗效和安全性：一项随机 3 期临床试验的 2 年结果。
Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14.
4
Urinary complement profile in IgA nephropathy and its correlation with the clinical and pathological characteristics.IgA 肾病的尿补体谱及其与临床和病理特征的关系。
Front Immunol. 2023 Mar 20;14:1117995. doi: 10.3389/fimmu.2023.1117995. eCollection 2023.
5
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.口服甲泼尼龙对 IgA 肾病患者肾功能下降或肾衰竭的影响：TESTING 随机临床试验。
JAMA. 2022 May 17;327(19):1888-1898. doi: 10.1001/jama.2022.5368.
6
Intensity of Macrophage Infiltration in Glomeruli Predicts Response to Immunosuppressive Therapy in Patients with IgA Nephropathy.肾小球内巨噬细胞浸润程度可预测 IgA 肾病患者对免疫抑制治疗的反应。
J Am Soc Nephrol. 2021 Dec 1;32(12):3187-3196. doi: 10.1681/ASN.2021060815.
7
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理临床实践指南。
Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
8
Prediction of corticosteroid responsiveness based on fibroblast-specific protein 1 (FSP1) in patients with IgA nephropathy.基于成纤维细胞特异性蛋白1（FSP1）对IgA肾病患者皮质类固醇反应性的预测
Nephrol Dial Transplant. 2008 Oct;23(10):3152-9. doi: 10.1093/ndt/gfn240. Epub 2008 May 7.
Zotero 插件